Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
965
datasets available to search
ShareScore release 0.9.0
Dataset results
965 results for “endocrine”
Sex-specific endocrine regulation of seasonal aggression in Siberian hamsters
<p>Coordinating physiological and behavioural processes across the annual cycle is essential in enabling individuals to maximize fitness. While the mechanisms underlying seasonal reproduction and its associated behaviours are well-characterized, fewer studies have examined the hormonal basis of non-reproductive social behaviours (e.g., aggression) on a seasonal timescale. Our previous work suggests that the pineal hormone melatonin facilitates a 'seasonal switch' in neuroendocrine regulation of aggression in male and female Siberian hamsters (Phodopus sungorus), specifically by acting on the adrenal glands to increase the production of the androgen dehydroepiandrosterone (DHEA) during the short-day (SD) photoperiods of the non-breeding season. Here, we provide evidence that the activity of 3β-hydroxysteroid dehydrogenase/∆5-∆4 isomerase (3β-HSD), a key enzyme within the steroidogenic pathway that mediates DHEA synthesis and metabolism, varies in a sex-specific and melatonin-dependent manner. Although both male and female hamsters displayed increased aggression in response to SDs and SD-like melatonin, only males showed an increase in adrenal 3β-HSD activity. Conversely, SD and melatonin-treated females exhibited reductions in both adrenal and neural 3β-HSD activity. Collectively, these results suggest a potential role for 3β-HSD in modulating non-breeding aggression and, more broadly, demonstrate how distinct neuroendocrine mechanisms may underlie the same behavioural phenotype in males and females.</p>
Endocrine profile of the vcd-induced perimenopausal model rat
<p>During the transition to menopause, women experience a variety of physical and psychological symptoms that are directly or indirectly linked to changes in hormone secretion. Establishing animal models with intact ovaries is essential for understanding these interactions and finding new therapeutic targets. In this study, we assessed the endocrine profile, as well as the estrous cycle, in the 4-vinylcyclohexene diepoxide (VCD)-induced follicular depletion rat model in 10-day intervals over 1 month to accurately establish the best period for studies of the transition period.</p>
A 4,302-patient cohort study of association of rare genetic alterations with endocrine disorders
<p><span>Endocrine pathologies including disorders such as diabetes and dysfunctions of endocrine glands, are frequently associated with genetic predisposition. This study investigated the association of endocrine diseases with genetic variants, copy number variations (CNVs), and mutational load of molecular pathways in 4302 patients with 409 ICD-10 diagnoses who underwent DNA testing using next-generation sequencing at the National Medical Research Center for Endocrinology (Moscow) from November 2017 </span><span>till</span><span> January 2024. We analyzed rare protein-altering genetic variants using three control cohorts (gnomAD3, RUSeq healthy, experimental).<span> </span>We identified 143 associated variants for diabetes mellitus and 188 genetic variants across other 18 different ICD-10 groups of diagnoses, including 25% and 30% of previously undescribed variants, respectively. In addition, we investigated the aggregation of genetic variants across individual genes and their functional ensembles (molecular pathways) and identified 105 and 101 associations with ICD-10 diagnoses, respectively. In addition, we identified 35 pathogenic and 91 likely pathogenic CNVs in 925 patients with whole exome sequencing profiles. Among them, 9 and 44 CNVs, respectively, were not previously described. Totally, we found statistically significant associations between CNVs and endocrine pathologies for 168 genes. These results expand our understanding of endocrine disease mechanisms and may indicate new potential therapeutic targets.</span></p>
Effects of COVID-19 in Endocrine Patients: A Cross-Sectional Study.
<p>Abstract: Introduction: Home confinement due to COVID-19 lockdown led to changes in daily<br> routines, including social interactions, as well as restrictions on the possibility of playing sports<br> and eating habits. These changes could have a greater impact on patients suffering from chronic<br> diseases, such as endocrine patients, especially in emotional and behavioral dimensions. Materials<br> and Methods: This study aimed to assess the effects of COVID-19-induced quarantine on daily habits<br> in a group of patients with endocrine disorders, focusing on food consumption, eating habits and<br> sleep during the confinement. Eighty-five endocrine patients were enrolled. A structured interview<br> was administered to investigate socio-demographic information, general medical conditions, and<br> habits adopted during quarantine. All patients underwent the Spielberger State Anxiety Inventory<br> (STAI-Y1) to assess state anxiety. Result: Results showed that subjects mainly had a sedentary lifestyle.<br> We found a significant increase in the number of cigarettes in smokers and in meals consumed during<br> confinement, as well as a high rate of sleep disturbance, especially insomnia. Notably, physical<br> well-being resulted to be a predictive factor (OR = 0.38; 95%CI = [0.95,0.66]), whereas anxiety was a<br> risk factor for sleep disorder (OR = 1.22; 95%CI = [1.10,1.40]), as was working in public and private<br> offices and being a student. Conclusions: Changes in daily habits were likely due to the alterations<br> in routine, resulting in greater boredom and inactivity during the day. In addition, future research<br> should focus on the importance of patient adherence to therapy.</p>
Positive p53 expression is significantly found higher in luminal B HER-2 negative cases with primary endocrine therapy resistance: A multicenter retrospective cross-sectional study in Indonesia
<p><strong>Positive p53 expression is significantly found higher in luminal B HER-2 negative cases with primary endocrine therapy resistance: A multicenter retrospective cross-sectional study in Indonesia</strong></p>
Analysis on CD8+/FOXP3+Ratio and Its Association with Primary Endocrine Therapy Resistance in Indonesian Luminal B Her-2 Negative BC Patients
<p>Analysis on CD8+/FOXP3+Ratio and Its Association with Primary Endocrine Therapy Resistance in Indonesian Luminal B Her-2 Negative BC Patients</p>
TBT exposure dataset of the manuscript "Assessment of endocrine disruptors effects on zebrafish (Danio rerio) embryos by untargeted LC-HRMS metabolomic analysis"
<p><strong>Raw LC-HRMS data of the TBT exposure of zebrafish embryos (for more details see https://doi.org/10.1016/j.scitotenv.2018.03.369)</strong></p> <p>The exposure protocol involved zebrafish embryos exposed in groups of 20 to various concentrations of chemical compounds, with five replicates per treatment. The concentrations ranged from the lowest observed effect concentrations (LOECs) to control levels. After exposure, embryos were collected, washed, frozen, and stored. Metabolites were extracted from individual embryo pools using methanol and methionine sulfone. The extraction process included vortexing, sonication, and centrifugation, followed by addition of water and chloroform. The aqueous fraction was dried and reconstituted using acetonitrile-water solution. Liquid chromatography coupled with high-resolution mass spectrometry (LC-HRMS) was used for analysis. Chromatographic separations were carried out on a hydrophilic interaction liquid chromatography (HILIC) column. Mass spectrometry was performed using an Orbitrap mass spectrometer with electrospray ionization in positive and negative modes. The mass spectra were acquired at high resolution, and fragmentation scans were used for metabolite identification. The overall process aimed to analyze the metabolomic profile of zebrafish embryos exposed to different chemical concentrations.</p> <p><strong>Data files</strong></p> <blockquote> <p>TBT ESI+ (tbt_pos.rar) - CDF files</p> <p>- QC (4 replicates)</p> <p>- Control (5 replicates)</p> <p>- TBT 3 nM (5 replicates)</p> <p>- TBT 10 nM (5 replicates)</p> <p>- TBT 30 nM (5 replicates)</p> <p>- TBT 100 nM (5 replicates)</p> </blockquote> <p> </p> <blockquote> <p>TBT ESI- (tbt_neg.rar) - CDF files</p> <p>- QC (6 replicates)</p> <p>- Control (5 replicates)</p> <p>- TBT 3 nM (5 replicates)</p> <p>- TBT 10 nM (5 replicates)</p> <p>- TBT 30 nM (5 replicates)</p> <p>- TBT 100 nM (5 replicates)</p> </blockquote>
The Magee 3 Equation Predicts Favorable Pathologic Response to Neoadjuvant Endocrine Therapy in Breast Cancer Patients
<p><strong>Supplementary Figure 1: </strong>Comparison between ROC curves of ME1, ME2, ME3, and MEm scores in a sample of breast cancer patients undergoing neoadjuvant endocrine therapy.</p> <p><strong>Supplementary Figure 2: </strong>ROC curves with their respective confidence intervals and AUC values in the sample of breast cancer patients, excluding those with clinical stage IA tumors. A: ME1. B: ME2. C: ME3. D: MEm.</p> <p><strong>Supplementary Figure 3:</strong> Comparison between ROC curves of ME1, ME2, ME3, and MEm scores in the sample of breast cancer patients undergoing neoadjuvant endocrine therapy (excluding those with clinical stage IA tumors).</p> <p> </p>
High CD8 + / FOXP3+ Ratio is Significantly Associated with Primary Endocrine Therapy Resistance Occurrence in Locally Advanced Luminal B Her-2 Negative Breast Cancer Patients
<p>High CD8 + / FOXP3+ Ratio is Significantly Associated with Primary Endocrine Therapy Resistance Occurrence in Locally Advanced Luminal B Her-2 Negative Breast Cancer Patients</p>
Supplemental Data for "Unraveling Vulnerabilities in Endocrine Therapy-Resistant HER2+/ER+ Breast Cancer"
<p>Supplemental data files for Bahnassy et al, "Unraveling Vulnerabilities in Endocrine Therapy-Resistant HER2+/ER+ Breast Cancer"</p>
A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative L
ClinicalTrials.gov study NCT04576455. IPD Sharing: YES. Countries: 17. Publications: 2.
The Aging Endocrine Pancreas: Characterization of the Entero-insular Axis Physiology in the Elderly
ClinicalTrials.gov study NCT00843479. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Effectiveness of a multicOmpoNent Behavioural intervenTion to Reduce endocrINe disrUptor Exposure During pErinatal Period (CONTINUE)
ClinicalTrials.gov study NCT07142447. IPD Sharing: NO. Countries: 1. Publications: 3.
The Summer Camp Study: Blood Glucose Control With a Bi-Hormonal Bionic Endocrine Pancreas
ClinicalTrials.gov study NCT01833988. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.
Renal, Endocrine, and Bone Changes in Response to FTC/TDF in Uninfected Young Men Who Have Sex With Men (YMSM).
ClinicalTrials.gov study NCT01769469. IPD Sharing: Not stated. Countries: 1. Publications: 3.
TRial on the Endocrine Activity of Neoadjuvant Degarelix
ClinicalTrials.gov study NCT02005887. IPD Sharing: Not stated. Countries: 1. Publications: 5.
A Study of Palbociclib in Addition to Standard Endocrine Treatment in Hormone Receptor Positive Her2 Normal Patients With Residual Disease After Neoadjuvant Chemotherapy and Surgery
ClinicalTrials.gov study NCT01864746. IPD Sharing: Not stated. Countries: 11. Publications: 9.
A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer
ClinicalTrials.gov study NCT04975308. IPD Sharing: YES. Countries: 22. Publications: 1.
Lapatinib and Trastuzumab With or Without Endocrine Therapy
ClinicalTrials.gov study NCT00548184. IPD Sharing: Not stated. Countries: 1. Publications: 2.
AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC)
ClinicalTrials.gov study NCT03959891. IPD Sharing: YES. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.